Consensus AtriCure, Inc.

Equities

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
29.72 ^USD	+2.91%		+5.28%	-24.87%

Feb. 18	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
Feb. 18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

75a6f19f75bd53e0eeb15999.19FSH_GGjMV5jRBIesd-cvtZBf1lIBGQKmCE0YZ8BdU.5eghR4WzxpAuwiR7KKgRFZIyfYUnEFzcaTXL_MNJN6a5phtTtMn6iizUfw~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

Feb. 18	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
Feb. 18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
Feb. 11	AtriCure Shares Fall After JPMorgan Downgrade	MT
Feb. 11	Top Midday Decliners	MT
Feb. 11	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
25-07-30	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
25-07-29	AtriCure Q2 revenue beats estimates	RE
25-04-30	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
25-03-28	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
25-02-13	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
24-10-30	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
24-07-31	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
24-05-02	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
24-04-23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
24-02-16	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
24-02-16	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
24-02-16	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
24-01-22	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23-10-23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
23-09-29	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
23-07-26	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
23-05-03	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
23-02-22	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT
23-02-22	Stifel Adjusts Price Target on AtriCure to $48 From $55, Maintains Buy Rating	MT
23-02-22	Canaccord Genuity Adjusts Price Target on AtriCure to $74 From $81, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					+57.3%
	ABBOTT LABORATORIES					+23.95%
	MEDTRONIC PLC					+26.56%
	CENCORA, INC.					+23.01%
	HOYA CORPORATION					+0.89%
	BECTON, DICKINSON AND COMPANY					+20.77%
	MEDLINE INC.					+12.34%
	DEXCOM, INC.					+35.78%
	STERIS PLC					+23.69%
	SARTORIUS STEDIM BIOTECH					+23.59%
	Average					+24.79%
	Weighted average by Cap.					+21.35%